📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
Granules India Q3FY26: Revenue Up 22% YoY to ₹13,879 Mn, PAT Grows 28%
Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and scaling of the complex generics portfolio. The company maintained a healthy ROCE of 16.8% and reduced its Net Debt/EBITDA ratio to 0.91x.
Key Highlights
Revenue increased 22% YoY to ₹13,879 Mn, with Europe sales surging 131% YoY to ₹2,344 Mn.
EBITDA grew 34% YoY to ₹3,081 Mn, with margins improving to 22.2% from 20.2% in the previous year.
Finished Dosage (FD) segment continues to dominate, contributing 76% of total revenue.
Complex generics portfolio expanded, driven by the scale-up of the ADHD portfolio in the US market.
US Packaging facility completed FDA inspection with zero observations, and ANVISA Brazil GMP certificate was received for the Gagillapur site.
👀 What to Watch
The company's strategic shift toward complex generics and finished dosages is yielding higher margins and robust growth. Investors should maintain a positive outlook given the strong regulatory compliance record and expanding presence in high-value markets like Europe.
Granules India Q3FY26 PAT Rises 28% YoY to ₹1,502 Mn; EBITDA Margins Expand to 22.2%
Granules India reported a strong Q3FY26 with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and operational efficiencies. The company also received a credit rating upgrade from ICRA to AA and reported zero observations for its US packaging facility.
Key Highlights
Revenue increased 22% YoY to ₹13,879 Mn, led by 131% growth in the European market.
EBITDA grew 34% YoY to ₹3,081 Mn with margins improving to 22.2% from 20.2% last year.
Finished Dosage (FD) segment remains the primary driver, contributing 76% of total revenue.
ICRA upgraded the company's credit rating from AA- to AA, reflecting improved financial stability.
R&D investment stood at ₹689 Mn (5% of sales), focusing on complex generics and oncology.
👀 What to Watch
The stock shows strong fundamental growth with margin expansion and a successful shift towards high-margin complex generics. Investors should maintain a positive outlook while monitoring the break-even timeline for the Peptides business.
Granules India Q3FY26 PAT Rises 28% YoY to INR 1,502 Mn; Revenue Up 22%
Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to INR 13,879 Mn, primarily driven by the Finished Dosages segment in North America and Europe. Profitability improved significantly as EBITDA rose 34% YoY to INR 3,081 Mn, with margins expanding to 22% from 20% in the previous year. Net profit (PAT) increased 28% YoY to INR 1,502 Mn, reflecting efficient execution and vertical integration. The company maintains a healthy balance sheet with a Net Debt to EBITDA ratio of 0.91x and a ROCE of 16.8%.
Key Highlights
Revenue from operations grew 22% YoY to INR 13,879 Mn, led by Finished Dosages which contributes 76% of total revenue.
EBITDA increased 34% YoY to INR 3,081 Mn, with margins improving to 22%.
PAT grew 28% YoY to INR 1,502 Mn, showing strong bottom-line momentum.
Net Debt to EBITDA remains conservative at 0.91x with total net debt at INR 10,151 Mn.
ROCE stood at 16.8% post the acquisition of Senn Chemicals AG, compared to 16.4% YoY.
👀 What to Watch
The company's strong operational momentum and margin expansion in regulated markets like North America and Europe are positive indicators. Investors should monitor the scaling of the Peptides/CDMO segment and the continued integration of Senn Chemicals for long-term value.
Granules India Q3 FY26 Net Profit Rises 23.8% YoY to ₹1,115.8M; Plans ₹17,625M Fundraising
Granules India reported a 6.3% YoY increase in standalone revenue to ₹8,953.18 million for Q3 FY26, with net profit growing 23.8% to ₹1,115.82 million. The company is navigating challenges from a USFDA warning letter at its Gagillapur facility, which has led to higher remediation costs and production slowdowns. A significant fundraising plan of approximately ₹17,625 million through warrants and equity at ₹585 per share has been approved to support growth. Additionally, the company completed the acquisition of Granules Pharmaceuticals GmbH in Germany and accounted for costs related to the Senn Chemicals AG acquisition.
Key Highlights
Standalone Net Profit increased by 23.8% YoY to ₹1,115.82 million in Q3 FY26.
Total Revenue from operations grew 6.3% YoY to ₹8,953.18 million.
Approved fundraising of ₹14,625 million via convertible warrants and ₹3,000 million via equity at ₹585/share.
Exceptional item of ₹121.60 million recorded for Senn Chemicals AG acquisition costs.
Ongoing remediation at Gagillapur facility following USFDA warning letter continues to impact margins via higher consultancy and freight costs.
👀 What to Watch
Investors should monitor the progress of the USFDA remediation at the Gagillapur plant and the utilization of the ₹17,625 million fundraise. The growth in profit despite regulatory hurdles is a positive sign, but the high remediation costs remain a near-term drag.
Granules India Shareholders Approve Issuance of 2.5 Crore Warrants and 51.28 Lakh Equity Shares
Granules India Limited held an Extraordinary General Meeting (EGM) on January 22, 2026, where shareholders approved two significant capital-raising resolutions. The first resolution involves the issuance of up to 2.5 crore warrants convertible into equity shares on a preferential basis, which passed with 86.69% support. The second resolution for the issuance of up to 51.28 lakh equity shares on a preferential basis received near-unanimous approval at 99.99%. These approvals provide the company with a mandate to raise capital through preferential allotments, likely aimed at funding future growth or strategic initiatives.
Key Highlights
Approved issuance of up to 2,50,00,000 warrants convertible into equity shares on a preferential basis.
Approved issuance of up to 51,28,205 equity shares on a preferential basis.
Warrant resolution passed with 86.69% majority, while the equity share resolution saw 99.99% approval.
A total of 73 shareholders participated in the meeting held via video conferencing.
The voting results were consolidated from both remote e-voting and e-voting during the EGM.
👀 What to Watch
Investors should look for subsequent disclosures regarding the allotment price and the specific identity of the allottees to assess potential equity dilution. The successful passage of these resolutions indicates strong shareholder backing for the company's capital expansion plans.
Granules India Issues Corrigendum for Rs 1,762.5 Cr Fundraise; Re-allocates Shares to 360 ONE Funds
Granules India has issued a corrigendum to its EGM notice regarding a preferential issue of equity shares and warrants totaling approximately Rs 1,762.5 crore. The primary change involves the removal of the Public Sector Pension Investment Board from the allottee list, with their portion re-allocated to various 360 ONE funds. The total issue size remains unchanged, and the proceeds are earmarked for capital expenditure, debt prepayment for its subsidiary Granules Life Sciences, and working capital. India Ratings & Research has been appointed as the monitoring agency for the fund utilization.
Key Highlights
Total fundraise size remains unchanged at approximately Rs 1,762.5 crore via equity and warrants.
Public Sector Pension Investment Board removed as an allottee; shares re-allocated to 360 ONE funds.
Rs 315 crore allocated for prepayment of term loans for subsidiary Granules Life Sciences Private Limited.
Rs 300 crore designated for capital expenditure in fixed assets, infrastructure, and technology over 24 months.
India Ratings & Research Private Limited appointed as the monitoring agency for issue proceeds.
👀 What to Watch
Investors should monitor the EGM outcome on January 22, 2026, as the capital infusion will significantly reduce debt and fund expansion. The re-allocation to 360 ONE funds indicates continued strong institutional interest despite the removal of one specific allottee.
Granules Gets US FDA Tentative Approval for Generic Dyanavel XR with 180-Day Exclusivity
Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release tablets, the generic version of DYANAVEL XR, used for ADHD treatment. Significantly, the company has secured 180-day exclusivity for this product, which addresses a market size of approximately USD 41 million. This marks the second major CNS-related tentative approval in weeks, following a December 2025 approval for a generic version of ADZENYS XR-ODT with a USD 172 million market. These developments highlight the company's successful pivot toward complex generics and differentiated products in the U.S. market.
Key Highlights
Received US FDA Tentative Approval for generic Amphetamine ER tablets (gDYANAVEL XR) in 5mg, 10mg, 15mg, and 20mg strengths.
Granted 180-day exclusivity by the FDA, ensuring a period of limited competition upon commercial launch.
Targets an addressable market size of approximately USD 41 million for the gDYANAVEL XR equivalent.
Follows a recent tentative approval for generic ADZENYS XR-ODT which has a USD 172 million market potential.
Strengthens Granules' portfolio in the complex Central Nervous System (CNS) therapeutic segment.
👀 What to Watch
Investors should monitor the transition from tentative to final approval and the subsequent launch timeline, as the 180-day exclusivity provides a high-margin opportunity. The company's growing pipeline of complex generics suggests a positive shift in its product mix toward higher-value segments.
Granules India to Raise ₹1,762.50 Cr via Preferential Issue of Warrants and Equity Shares
Granules India has scheduled an Extraordinary General Meeting on January 22, 2026, to approve a total fundraise of ₹1,762.50 crores. The company plans to issue 2.5 crore convertible warrants to the promoter group at ₹585 each, totaling ₹1,462.50 crores. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors, including 360 ONE funds and the Public Sector Pension Investment Board, raising ₹300 crores. This significant capital infusion, largely backed by promoters, indicates strong internal confidence in the company's growth trajectory.
Key Highlights
Issuance of 2.5 crore warrants to the promoter group at ₹585 per warrant, totaling ₹1,462.50 crores.
Preferential allotment of 51.28 lakh equity shares to institutional investors at ₹585 per share, raising ₹300 crores.
Total capital infusion of ₹1,762.50 crores to be approved at the EGM on January 22, 2026.
Warrant terms require 25% payment upfront with the remaining 75% payable upon conversion within 18 months.
Key institutional participants include various 360 ONE funds and the Public Sector Pension Investment Board.
👀 What to Watch
Investors should take the significant promoter participation as a positive signal of long-term commitment and confidence. Monitor upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Granules India to Raise Rs 1,762.50 Crore via Preferential Issue of Shares and Warrants
Granules India's board has approved a massive fundraise of Rs 1,762.50 crore through a mix of equity shares and convertible warrants. The company will issue 2.5 crore warrants at Rs 585 each, primarily to the promoter group, totaling Rs 1,462.50 crore. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors like 360 ONE and Public Sector Pension Investment Board for Rs 300 crore. This capital infusion is subject to shareholder approval at an EGM scheduled for January 22, 2026.
Key Highlights
Total fundraise of Rs 1,762.50 crore at a fixed price of Rs 585 per share/warrant.
Issuance of 2.5 crore convertible warrants to promoters and others, aggregating Rs 1,462.50 crore.
Issuance of 51.28 lakh equity shares to non-promoter institutional investors for Rs 300 crore.
Major institutional participants include 360 ONE funds and Public Sector Pension Investment Board.
Warrants require 25% upfront payment and are convertible within 18 months from allotment.
👀 What to Watch
Investors should view the significant promoter participation and institutional backing as a strong vote of confidence. Monitor the upcoming EGM on January 22, 2026, and the company's plans for utilizing this capital for growth.
Granules Receives US FDA Tentative Approval for Generic ADHD Drug with $172M Market Size
Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release Orally Disintegrating Tablets, a generic version of ADZENYS XR-ODT®. The product targets the ADHD treatment market, which has an estimated annual size of USD 172 million according to IQVIA. This approval is significant as the market currently has limited competition with only one approved generic and one authorized generic available. The drug will be manufactured at the company's facility in Chantilly, Virginia, emphasizing their focus on complex dosage forms.
Key Highlights
Received US FDA tentative approval for generic Amphetamine ER Orally Disintegrating Tablets in 6 strengths.
Targets a significant US market opportunity estimated at USD 172 million per IQVIA data.
Limited competition environment with only one approved generic and one authorized generic currently in the market.
Product to be manufactured at Granules' US-based facility in Chantilly, Virginia.
Strengthens the company's portfolio in the Central Nervous System (CNS) therapeutic area.
👀 What to Watch
Investors should monitor the transition from tentative to final approval and the subsequent commercial launch timeline. This development strengthens Granules' US generic pipeline in a high-barrier, limited-competition segment.
Granules India Subsidiary Completes USFDA Inspection with 5 Procedural Observations
Granules India's wholly-owned subsidiary, Granules Life Sciences (GLS), underwent a USFDA inspection at its Hyderabad facility from December 15 to 19, 2025. The inspection, which covered Good Manufacturing Practices (GMP) and Prior Approval, concluded with 5 observations. Management has clarified that these observations are strictly procedural and do not relate to data integrity or product safety. The company is committed to responding to the USFDA within the stipulated timeframe to resolve these points.
Key Highlights
USFDA inspection conducted at the Hyderabad facility (FEI: 3030495702) from December 15 to 19, 2025.
The audit concluded with 5 observations related to procedural requirements.
Zero observations were reported regarding data integrity or product safety, reducing the risk of severe regulatory action.
The facility is operated by Granules Life Sciences Private Limited and manufactures PFI and Finished Dosages.
👀 What to Watch
Investors should monitor the final classification of the inspection report; while 5 observations require attention, the lack of data integrity issues is a positive sign. Maintain a watch on the company's ability to resolve these procedural gaps without impacting future product approvals.
Granules India receives 'A' rating in Climate Change from CDP
Granules India Limited has received an 'A' rating in Climate Change from the Carbon Disclosure Project (CDP), a two-level improvement from its 'B' rating in 2024. The company also achieved a 'B' rating in Water Security and a 'B-' rating in Forests in its first disclosure. These ratings reflect Granules India's commitment to sustainability and climate responsibility. Investors should note the company's increasing focus on environmental transparency and performance, which could positively influence long-term value.
Key Highlights
Received 'A' rating in Climate Change from CDP, up from 'B' in 2024
Achieved 'B' rating in Water Security
Received 'B-' rating in Forests in first disclosure
👀 What to Watch
Investors should view this improved CDP rating as a positive signal regarding Granules India's commitment to environmental sustainability. Monitor future disclosures and initiatives related to ESG (Environmental, Social, and Governance) factors.
Granules India receives 'A' rating in Climate Change from CDP
Granules India Limited has received an 'A' rating in Climate Change from the Carbon Disclosure Project (CDP), a two-level improvement from its 'B' rating in 2024. The company also received a 'B' rating in Water Security and a 'B-' rating in Forests in its first disclosure. These ratings reflect Granules India's commitment to sustainability and climate responsibility. Investors should note this improvement as a positive indicator of the company's ESG performance.
Key Highlights
Received 'A' rating in Climate Change from CDP, up from 'B' in 2024
Achieved 'B' rating in Water Security
Received 'B-' rating in Forests in the first disclosure
👀 What to Watch
Investors should view this improved CDP rating as a positive signal regarding Granules India's commitment to environmental sustainability. Monitor future ESG reports for continued progress.
Granules India US Packaging Facility Clears US FDA Inspection with Zero Observations
Granules India's US-based subsidiary, Granules Consumer Health, LLC, has successfully cleared a US FDA GMP inspection with zero observations. The facility, which operates three advanced packaging lines, serves as a critical hub for the company's over-the-counter (OTC) products and controlled substances in the United States. This marks the second consecutive successful audit for the site, following a No Action Indicated (NAI) classification in March 2023. The outcome reinforces the company's regulatory compliance standing and ensures the stability of its US front-end distribution operations.
Key Highlights
US FDA inspection of Granules Consumer Health, LLC facility completed with zero observations.
Facility operates 3 advanced packaging lines for OTC products and controlled substances.
Second successful FDA audit for the site, following a March 2023 NAI classification.
The facility serves as the primary front-end division for Granules' OTC products in the US market.
👀 What to Watch
This regulatory clearance mitigates the risk of supply chain disruptions in the critical US market. Investors should view this as a validation of the company's robust quality systems and operational stability.
Granules India Opens Two R&D Centres of Excellence at IIT Hyderabad for Peptides and Engineering
Granules India has inaugurated two advanced Centres of Excellence (CoE) at the IIT Hyderabad Technology Research Park to bolster its R&D and CDMO capabilities. The Ascelis CoE focuses on peptide development and characterization, marking its first such facility in India, while the Particle Engineering CoE will focus on material science and novel drug delivery systems. These facilities aim to reduce reliance on external partners and create first-to-file opportunities in regulated markets. The company currently operates 11 manufacturing facilities globally and serves over 300 customers across 80 countries.
Key Highlights
Inaugurated the Ascelis Center for Peptide Development and the Granules Center for Particle Engineering at IIT Hyderabad.
The Ascelis CoE is the company's first Indian facility dedicated to cosmetic, therapeutic, and pharmaceutical peptide characterization.
The Particle Engineering CoE focuses on polymorph research and amorphous solid dispersions to enable first-to-file opportunities.
New centres will collaborate with Swiss-based Senn Chemicals to provide an integrated global peptide offering.
Granules India maintains a global footprint with 11 manufacturing facilities across India, USA, and Switzerland.
👀 What to Watch
Investors should monitor the company's transition toward high-margin CDMO and peptide segments facilitated by these R&D investments. This move strengthens the long-term product pipeline and competitiveness in regulated markets.
